Esophageal Cancer Clinical Trial
Official title:
Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer
Verified date | April 2023 |
Source | Stemirna Therapeutics |
Contact | Li Yang |
Phone | 0371-66295320 |
yanglizzuyl[@]163.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 31, 2025 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Aged between 18 and 75 (including both ends), with no gender limit; - The primary lesion was confirmed by histopathology or cytology as esophageal carcinoma (?C (T4bNanyM0, TanyN3M0), and stage ?) or non-small cell lung cancer (stage ?B-?). - Patients who have metastatic or locally advanced tumor but failed instandard treatments or not suitable for standard treatments; - According to RECIST (V1.1), the efficacy evaluation criteria for solid tumors, there is at least one measurable lesion. - Participants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) PS - Participants must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry - Fertile patients must agree to use a reliable contraceptive methods (hormonal or barrier methods or abstinence) during the trial and for at least 12 weeks after the last treatment; - The subject voluntarily participates and signs ICF (Informed consent forms). Exclusion Criteria: - Any clinical research drugs, anti-cancer monoclonal antibodies, anti-cancer therapeutic vaccines, immunostimulants (such as IL-2) or using previous investigational drugs within 7 days of the first treatment with mRNA-personalized tumor vaccine or carrelizumab. - Patients who have allergies or previous history of biological drug allergy; - Patients who are in pregnant or breast-feeding; - Patients who are expected to survive less than 3 months during the screening period; - Tumor mutation load (TMB) is less than 2.0/Mb or tumor neogenic antigen load (TNB) is less than 0.5/Mb or the number of predicted neoantigen is less than 3; - Patients who underwent major surgery or suffered significant trauma within 4 weeks prior to the enrollment (blood collection), or who are expected to undergo major surgery during the study period; - Patients with symptoms of brain metastases (Patients with stable brain metastases can be included) - Extensive lung metastases from tumors, causing breathing difficulties; - Patients who have tumors close to large blood vessels or nerves; - A history of severe cardiovascular and cerebrovascular diseases, including but not limited to ventricular arrhythmia requiring clinical intervention; Acute coronary syndrome, myocardial infarction, congestive heart failure, stroke or other grade III and above cardiovascular events within 6 months; New York Heart Association (NYHA) cardiac function grade=Grade II or left ventricular ejection fraction (LVEF) <50%; Poorly controlled hypertension after standard treatment (systolic blood pressure> 150 mmHg and diastolic blood pressure> 90 mmHg); - Patients with active ulcers and gastrointestinal bleeding; - Patients with clinically confirmed autoimmune disease have received systemic treatment in the past 2 years; HIV, HCV positive; HBV-DNA=1×103 copies/mL (or 2×102 IU/mL); Acute EBV or CMV virus infection; - Patients with previous history of non-infectious pneumonia requiring steroid therapy or acute lung cancer; - Participants with a history of interstitial lung disease; - Patients who have a history of organ transplantation or are waiting for organ transplantation; - Have any uncontrolled active infection; - Immunosuppressed subjects, including those with known immunodeficiency; those who are currently using steroids systemically (except those who are using inhaled steroids recently or currently); - Skin diseases (such as psoriasis) may prevent intradermal vaccines from reaching the target area; - Who have received chemotherapy, biotherapy, radiotherapy, endocrine therapy, targeted therapy and other tumor treatments, or other experimental drug treatments, or surgery (excluding diagnostic biopsy) within 7 days prior to the first administration of mRNA tumor vaccine treatment; - Adverse effects from previous antitumor therapy have not recovered referred to CTCAE (V5.0) rating =1 (except hair loss); - The investigator evaluates that the subject is unable or unwilling to comply with the requirements of study protocol. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Stemirna Therapeutics | The First Affiliated Hospital of Zhengzhou University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all = grade 3 adverse events per CTCAE will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below:
Fever Chills Nausea, vomiting and other gastrointestinal symptoms Fatigue Hypotension Respiratory distress Tumor lysis syndrome Neutropenia, thrombocytopenia Liver and kidney dysfunction Neutropenia, thrombocytopenia Liver and kidney dysfunction |
24 weeks | |
Secondary | Disease Control Rate (DCR) | Disease Control Rate of Personalized mRNA Tumor Vaccine | 1.5 years | |
Secondary | Progression-free Survival (PFS) | Progression-free Survival of Personalized mRNA Tumor Vaccine | 2 years | |
Secondary | Time to Tumor Progression (TTP) | Time to Tumor Progression of Personalized mRNA Tumor Vaccine | 2 years | |
Secondary | Overall Survival (OS) | Overall Survival of Personalized mRNA Tumor Vaccine | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 |